It is tempting to speculate with respect to cancers that the IFITMs could potentially function in a broadly analogous manner to negative regulatory ISGs such as TREX1 and ADAR1, which negatively regulate antitumor immunity and thereby promote therapy resistance (Fig. 1) (46, 103). This evidence concerns the gene TREX1 and cancer.